Envoy Medical (NASDAQ: COCHW) gets European cochlear patent grant

Rhea-AI Filing Summary

Envoy Medical, Inc. filed a current report to disclose that it has received a European patent titled “Implantable Cochlear System with Integrated Components and Lead Characterization.” This patent relates to the company’s implantable cochlear system technology.

The company announced the patent in a press release dated September 19, 2025, which is included as Exhibit 99.1 to the report and incorporated by reference.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false 0001840877 0001840877 2025-09-19 2025-09-19 0001840877 COCH:ClassCommonStockParValue0.0001PerShareMember 2025-09-19 2025-09-19 0001840877 COCH:RedeemableWarrantsEachWholeWarrantMember 2025-09-19 2025-09-19 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 19, 2025

ENVOY MEDICAL, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-40133		86-1369123
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

4875 White Bear Parkway White Bear Lake, MN		55110
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (877) 900-3277

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Class A Common Stock, par value $0.0001 per share		COCH		The Nasdaq Stock Market LLC
Redeemable Warrants, each whole Warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50 per share		COCHW		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events

On September 19, 2025, Envoy Medical, Inc. (the “Company”) issued a press release announcing the Company's receipt of a European patent titled “Implantable Cochlear System with Integrated Components and Lead Characterization.”

A copy of the press release is attached hereto and incorporated by reference herein as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number		Description
99.1		Envoy Medical, Inc. Press Release, dated September 19, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ENVOY MEDICAL, INC.
September 19, 2025	By:	/s/ Brent T. Lucas
		Brent T. Lucas
		Chief Executive Officer

2

FAQ

What did Envoy Medical (COCHW) report in this 8-K filing?

Envoy Medical reported that it received a European patent titled “Implantable Cochlear System with Integrated Components and Lead Characterization,” and furnished a related press release as an exhibit.

What is the title of Envoy Medical’s new European patent?

The European patent is titled “Implantable Cochlear System with Integrated Components and Lead Characterization.”

When did Envoy Medical announce the European patent covered in this filing?

Envoy Medical announced the European patent in a press release dated September 19, 2025, the same date as the event reported.

Which exhibit in the 8-K contains details about Envoy Medical’s patent announcement?

Exhibit 99.1 contains Envoy Medical’s press release dated September 19, 2025, describing the European patent announcement.

On which exchange is Envoy Medical’s Class A common stock listed and under what symbol?

Envoy Medical’s Class A common stock is listed on The Nasdaq Stock Market LLC under the trading symbol COCH.

What securities of Envoy Medical related to COCHW are mentioned in the filing?

The filing notes redeemable warrants, each whole warrant exercisable for one share of Class A common stock at an exercise price of $11.50 per share, trading under the symbol COCHW on The Nasdaq Stock Market LLC.